1. Home
  2. KURA

as 03-31-2025 2:39pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 592.7M IPO Year: N/A
Target Price: $25.50 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.02 EPS Growth: N/A
52 Week Low/High: $6.79 - $23.48 Next Earning Date: 05-01-2025
Revenue: $53,883,000 Revenue Growth: N/A
Revenue Growth (this year): 13.15% Revenue Growth (next year): 221.86%

KURA Daily Stock ML Predictions

Stock Insider Trading Activity of Kura Oncology Inc. (KURA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Bair Teresa Brophy KURA Chief Legal Officer Jan 28 '25 Sell $7.87 7,281 $57,315.30 112,792
DOYLE THOMAS JAMES KURA SVP, Finance & Accounting Jan 28 '25 Sell $7.87 4,949 $38,958.03 90,014
FORD KATHLEEN KURA Chief Operating Officer Jan 28 '25 Sell $7.87 1,817 $14,303.24 21,367
Powl Brian T. KURA Chief Commercial Officer Jan 28 '25 Sell $7.87 1,583 $12,461.22 59,667
Leoni Mollie KURA Chief Medical Officer Jan 28 '25 Sell $7.87 4,963 $39,068.24 88,253
Burrows Francis KURA Chief Scientific Officer Jan 28 '25 Sell $7.87 2,166 $17,050.54 20,705

Share on Social Networks: